Impact of COVID-19 Vaccination on Balance Function Among Adolescents: A Long-Term Perspective

July 12, 2025 updated by: Alaa Noureldeen Kora, Sinai University
Long term impact of COVID 19 vaccination on dizziness-related disability and balance in adolescence

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

270

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Ismailia, Egypt, 11749
        • Sinai university

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

  • Adolescence age range 10-17
  • Vaccinated by any available SARS -COV-2 Vaccinations

Description

Inclusion Criteria:

  • Adolescence age range 10-17
  • received a dose or more of an approved COVID-19 vaccine at least one year before the study enrollment.

the ability to complete all assessment measures independently.

Exclusion Criteria:

  1. vestibular or neurological disorders diagnosed before vaccination.
  2. mixed COVID-19 vaccine types.
  3. a history of traumatic brain injury.
  4. current use of medications that affect balance.
  5. documented COVID-19 infection within three months of assessment.
  6. physical limitations that prevented them from completing balance testing.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional Disability
Time Frame: Through study completion, an average of 1 day - 1 year after taking the vaccine
The Dizziness Handicap Inventory is used to assess functional disability related to dizziness
Through study completion, an average of 1 day - 1 year after taking the vaccine
Impact on Balance
Time Frame: Through study completion, an average of 1 day - 1 year after taking the vaccine
The pediatric balance scale is used to assess balance (Lowest score =0 " worst"- Maximum score is 56 " Perfect Balance"
Through study completion, an average of 1 day - 1 year after taking the vaccine

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Emotional Disability
Time Frame: Through study completion, an average of 1 day - 1 year after taking the vaccine
The Dizziness Handicap Inventory is used to assess emotional disability related to dizziness
Through study completion, an average of 1 day - 1 year after taking the vaccine
Physical Disability
Time Frame: Through study completion, an average of 1 day - 1 year after taking the vaccine
The Dizziness Handicap Inventory is used to assess physical disability related to dizziness
Through study completion, an average of 1 day - 1 year after taking the vaccine

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sinai University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 6, 2023

Primary Completion (Actual)

April 30, 2024

Study Completion (Actual)

July 1, 2024

Study Registration Dates

First Submitted

August 11, 2023

First Submitted That Met QC Criteria

July 12, 2024

First Posted (Actual)

July 16, 2024

Study Record Updates

Last Update Posted (Actual)

July 16, 2025

Last Update Submitted That Met QC Criteria

July 12, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • P.T.REC/012/005002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on SARS CoV 2 Vaccination

Clinical Trials on SARS-COV-2 vaccination

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe